Answers are grounded in this paper and cite their sources.
The effect of polyvinyl pyrrolidone (PVP) K30 and/or L-arginine on etoricoxib-HPbetaCD complex was investigated. The phase solubility profiles were classified as A(L)-type, both in absence or presence of auxiliary substances used. The apparent stability constant (K(c)) of binary complex obtained at room temperature, 371.80 +/- 2.61 M(-1), was decreased with the addition of PVP and arginine indicating no benefit of addition of auxiliary substances to promote higher complexation efficiency. Therefore, solid etoricoxib-HPbetaCD binary systems were prepared and characterized by proton nuclear magnetic resonance spectroscopy (1HNMR), X-ray powder diffractometry, Fourier transformation-infrared spectroscopy, and dissolution studies. Among all binary systems, a lyophilized product showed superior performance in enhancing dissolution of etoricoxib.
No takes yet. Share an insight, caveat, or question.
Shah et al. (2008) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: